Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer

José Baselga*, Patricia Gómez, Richard Greil, Sofia Braga, Miguel A. Climent, Andrew M. Wardley, Bella Kaufman, Salomon M. Stemmer, António Pego, Arlene Chan, Jean Charles Goeminne, Marie Pascale Graas, M. John Kennedy, Eva Maria Ciruelos Gil, Andreas Schneeweiss, Angela Zubel, Jutta Groos, Helena Melezínkova, Ahmad Awada

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

303 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience